Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
62.835,89
-1,42%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Lipocine Inc (LPCN) Lipocine Inc (LPCN) Notizie

Lipocine Inc

LPCN
4,7983
0,2483 (5,46%)
26 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
11/4/202413:00PRNUSLipocine Announces Positive LPCN 2401 Clinical Results..
28/3/202413:00PRNUSLipocine Announces Positive Week 52 Results from LPCN 1148..
25/3/202413:00PRNUSLipocine Announces First Cohort Dosed in Pivotal Study of..
07/3/202423:31EDGAR2Form 8-K - Current report
07/3/202414:00PRNUSLipocine Announces Financial Results for the Full Year Ended..
07/3/202412:08EDGAR2Form 8-K - Current report
07/3/202412:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/3/202414:00PRNUSLipocine to Present at 36th Annual Roth Conference
06/3/202412:01EDGAR2Form 8-K - Current report
12/2/202422:10EDGAR2Form 8-K - Current report
06/2/202414:00PRNUSLipocine Announces Confirmation of Dosing Regimen for..
02/2/202414:00PRNUSLipocine Announces Continued Commercialization of TLANDO®..
18/1/202414:20EDGAR2Form 8-K - Current report
18/1/202414:00PRNUSLipocine and Verity Pharma Enter into License Agreement for..
19/12/202316:00EDGAR2Form 8-K - Current report
19/12/202314:00PRNUSLipocine to Present at Biotech Showcase 2024
22/11/202322:15EDGAR2Form S-3 - Registration statement under Securities Act of..
13/11/202320:45EDGAR2Form 8-K - Current report
13/11/202320:45PRNUSLipocine Releases Late Breaking Presentation on LPCN 1148..
08/11/202319:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:50EDGAR2Form 8-K - Current report
08/11/202314:00PRNUSLipocine Announces Financial Results for the Third Quarter..
01/11/202314:31EDGAR2Form 8-K - Current report
01/11/202313:00PRNUSLipocine to Present Clinical Data on LPCN 1148 at The Liver..
26/10/202315:35EDGAR2Form 8-K - Current report
26/10/202314:00PRNUSLipocine Completes Successful Meeting with FDA on LPCN 1154..
24/10/202301:00PRNUSLipocine to Present at the H.C. Wainwright Annual NASH..
06/10/202322:05EDGAR2Form 8-K - Current report
19/9/202322:10EDGAR2Form 8-K - Current report
19/9/202322:05PRNUSLipocine to Present at the Cantor Fitzgerald Global..
10/8/202314:35EDGAR2Form 8-K - Current report
10/8/202314:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202314:00PRNUSLipocine Announces Financial Results for the Second Quarter..
27/7/202312:45EDGAR2Form 8-K - Current report
27/7/202312:30PRNUSLPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients..
14/6/202314:00PRNUSLipocine to Present at H.C. Wainwright Annual..
07/6/202314:00PRNUSLipocine to Present LPCN 1148 and LPCN 1144 at the EASL..
16/5/202313:00PRNUSPositive Topline Clinical Results Support Streamlined..
11/5/202312:00PRNUSLipocine Announces Financial Results for the First Quarter..
Apertura: 4,52 Min: 4,38 Max: 4,8099
Chiusura: 4,55

La tua Cronologia

NASDAQ
LPCN
Lipocine
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network